In this issue:
Ruxolitinib for steroid-refractory chronic GVHD after allogeneic HSCT
Sitagliptin for acute GVHD prophylaxis
Ropeginterferon alfa-2b vs. phlebotomy in low-risk polycythaemia vera
Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1-mutated AML
Predictors of poor outcome in sickle cell disease with COVID
Single low-dose rasburicase for managing TLS in leukaemia/lymphoma patients
Outcomes after allogeneic HSCT in adults with PNH
Venetoclax induces deep haematological remission in t(11;14) AL amyloidosis
Lenalidomide vs. bortezomib maintenance after autologous SCT for MM
No increase in thrombosis risk after RBC transfusion
Please login below to download this issue (PDF)